Kenvue Inc. $KVUE Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 49,862,574 shares of the company’s stock after buying an additional 371,322 shares during the quarter. Geode Capital Management LLC’s holdings in Kenvue were worth $856,778,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cornerstone Planning Group LLC increased its stake in Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. raised its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. Elyxium Wealth LLC purchased a new stake in Kenvue in the fourth quarter valued at $26,000. Golden State Wealth Management LLC raised its position in Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after purchasing an additional 1,190 shares during the period. Finally, SBI Securities Co. Ltd. raised its position in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE:KVUE opened at $17.29 on Friday. The company has a fifty day simple moving average of $17.40 and a two-hundred day simple moving average of $17.46. The company has a market cap of $33.19 billion, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 1.34 and a beta of 0.55. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $23.90.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.24 earnings per share. As a group, equities analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s payout ratio is 97.65%.

Analyst Ratings Changes

Several brokerages have weighed in on KVUE. Barclays lowered their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Canaccord Genuity Group increased their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Finally, Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus target price of $19.33.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.59% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.